Title: “Home Run: Promising Results for Immunotherapy Add-on in Advanced Endometrial Cancer Treatment”Body:A new study has shown promising results for an immunotherapy add-on treatment in advanced endometrial cancer. The study, published in the Journal of Clinical Oncology, found that adding the immunotherapy drug pembrolizumab to standard chemotherapy improved overall survival in patients with advanced endometrial cancer
Endometrial cancer is the most common gynecologic cancer in the United States, with an estimated65,620 new cases in2021. While many women with endometrial cancer are cured with surgery and/or radiation therapy, those with advanced or recurrent disease have limited treatment options and poor outcomes
The study included577 patients with advanced endometrial cancer who were randomly assigned to receive either standard chemotherapy alone or chemotherapy plus pembrolizumab. The addition of pembrolizumab was associated with a significant improvement in overall survival, with a median survival of17.4 months compared to12.0 months with chemotherapy alone
Furthermore, the combination treatment was well-tolerated, with manageable side effects. The most common side effects were fatigue, nausea, and anemia
Immunotherapy has revolutionized cancer treatment in recent years, offering new hope to patients with previously untreatable cancers. This study adds to the growing body of evidence supporting the use of immunotherapy in gynecologic cancers, particularly in the treatment of advanced endometrial cancer
The results of this study are a home run for patients with advanced endometrial cancer, offering a new treatment option that can improve survival and quality of life. We look forward to further research in this area and hope to see this treatment become more widely available to those who need it.